IRF9 and cancer: Likewise, elevated U-ISGF3 has also separately been shown to drive the expression of an IFN-related DNA damage resistance signature (IRDS), which correlates with therapeutic resistance and poor prognosis in a variety of cancers, including breast cancers [13, 14].